Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCTC21C in newly diagnosed systemic light-chain amyloidosis
NCT07388602Phase 3Recruiting
- Sponsor
- Sinocelltech Group Limited
- Start
- Jan 2026
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of SCTC21C in light-chain amyloidosis, sponsored by Sinocelltech Group Limited. Started Jan 2026; status: recruiting.
02
Drugs
SCTC21C
03
Conditions
light-chain amyloidosis
Beyond the preview
Go deeper on NCT07388602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07388602.